Medroxyprogesterone therapy for sexual precocity in girls

An evaluation of 13 girls who had been treated intramuscularly with medroxyprogesterone acetate for sexual precocity showed that this drug has no effect on growth, skeletal maturation, or adult height. During treatment (mean duration, 3.6 years), menstruation was suppressed and breast size initially regressed, but breast development and public hair development progressed during long-term therapy. The extent of delay in resumption of menses after cessation of therapy was related both to duration of treatment and dosage of the drug.